Hermes gets FDA clearance for radiation dose software

Hermes Medical Solutions has received 510(k) clearance from the U.S. Food and...Read more on AuntMinnie.comRelated Reading: Hermes launches new radiation therapy software Hermes appoints new president, CEO Hermes launches new liver analysis software Hermes expands North America executive team Hermes, Vanderbilt collaborate on dosimetry application
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Purpose of review To provide a framework for approaching ventricular arrhythmias in the setting of cardiomyopathy, outline the latest evidence-based recommendations for catheter ablation and device therapy, and discuss novel treatment strategies. Recent findings Risk stratification of ventricular arrhythmias in systolic heart failure has evolved, with an increasing role for cardiac magnetic resonance imaging to identify underlying substrate and scar burden. Medical therapy for heart failure has greatly improved, and the role of primary prevention defibrillators in nonischemic cardiomyopathy has become more ambiguous. ...
Source: Current Opinion in Cardiology - Category: Cardiology Tags: CARDIAC FAILURE: Edited by Rebecca Cogswell and Gene Kim Source Type: research
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
The objective of the survey was to generate baseline data to inform requirements for a networked approach to the implementation of new radiation therapy techniques and technologies. All radiation therapy services in NSW were contacted by email with a request to complete a SABR service survey. Questions were designed to identify equipment used, treatment techniques in place, clinical sites treated with a SABR technique and plans to expand the current services offered. Each professional group was asked to identify areas of service delivery they would most like to improve. Sixteen responses were received representing 24 of 27...
Source: Australasian Physical and Engineering Sciences in Medicine - Category: Biomedical Engineering Source Type: research
FDA has granted de novo classification to a non-surgical device for the minimally invasive treatment of Benign Prostatic Hyperplasia (BPH). The iTind device was developed by Or Akiva, Israel-based Medi-Tate. However, Olympus holds the exclusive right to distribute iTind in the U.S. Here’s how iTind works. The flexible three-strut nitinol device can be placed during an in-office procedure. It expands over five days to create channels that allow urine to flow and reshape the prostate. In a release, Nacho Abia, COO of Olympus Corporation and CEO of Olympus Corporation of the Americas said, "Our investme...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news
ConclusionsCurrent clinical trials are exploring combination therapy and novel treatment strategies beyond immune checkpoint therapies and vaccine therapy such as CAR T cells. There is also an effort to establish synergy between immunotherapy and current standard of care. Furthermore, recent advances in personalized neoantigen vaccines suggest a shift towards personalized, patient-specific GBM treatment.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
This study investigated the improvement of patient setup accuracy and reduction of setup time for SGRT compared to a conventional setup. A total of 60 H&N cancer patients were retrospectively included. Patients were categorized into three groups: oral cavity, oropharynx and nasopharynx/sinonasal sites with 20 patients in each group. They were further separated into two (2) subgroups, depending on whether they were set up with the aid of SGRT. The Align-RT™ system was used for SGRT in this work. Positioning was confirmed by daily kV-kV imaging in conjunction with weekly CBCT scans. Translational and rotational couch s...
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
SpaceOAR© hydrogel rectal dose reduction prediction model: a decision support tool. J Appl Clin Med Phys. 2020 Apr 06;: Authors: Paetkau O, Gagne IM, Alexander A Abstract Prostate cancer external beam radiation therapy can result in toxicity due to organ at risk (OAR) dose, potentially impairing quality of life. A polyethylene glycol-based spacer, SpaceOAR© hydrogel (SOH), implanted between prostate gland and rectum may significantly reduce dose received by the rectum and hence risk of rectal toxicity. SOH implant is not equally effective in all patients. Determining patients in which the im...
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
CONCLUSION: The pDJDC technique allows treatment of multiple targets in almost half the time of the HDJ technique. The pDJDC plans were comparable to the HDJ plans in dose distribution, although the conformity index deteriorated. PMID: 32250015 [PubMed - as supplied by publisher]
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
ConclusionThe repeated courses of LD ‐RT offered similar efficacy compare with the first course in patients with indolent B‐NHL. LD‐RT repeated is a simple, easy to give, and non‐toxic asset that could be investigated as treatment option in patients with indolent B‐NHL.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
uglakos Immunotherapy has considerably increased the number of anticancer agents in many tumor types including metastatic colorectal cancer (mCRC). Anti-PD-1 (programmed death 1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) immune checkpoint inhibitors (ICI) have been shown to benefit the mCRC patients with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). However, ICI is not effective in mismatch repair proficient (pMMR) colorectal tumors, which constitute a large population of patients. Several clinical trials evaluating the efficacy of immunotherapy combined with che...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Liver | Radiation Therapy | Radiology | Urology & Nephrology